Genus Oncology, LLC
Records under this name other than the patents Genus Oncology, LLC holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned. None of them is counted in the 5 patents it holds.
Showing 1 to 9 of 9 · Back to Genus Oncology, LLC
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 8,524,669 | MUC-1 Cytoplasmic Domain Peptides as Inhibitors of Cancer Formerly held In force · High confidence | In force | High confidence | |
| US 8,685,928 | Antagonists of MUC1 Formerly held In force · High confidence | In force | High confidence | |
| US 9,044,421 | Treating MUC1-EXPRESSING Cancers with Combination Therapies Formerly held In force · High confidence | In force | High confidence | |
| US 10,059,775 | Antibodies Against the MUC1-C/EXTRACELLULAR Domain (MUC1-C/ECD) Formerly held In force · High confidence | In force | High confidence | |
| US 11,136,410 | Antibodies Against the MUC1-C/EXTRACELLULAR Domain (MUC1-C/ECD) Formerly held In force · High confidence | In force | High confidence | |
| US 12,466,895 | Antibodies Against the MUC1-C/EXTRACELLULAR Domain (MUC1-C/ECD) Formerly held In force · High confidence | In force | High confidence | |
| US 10,617,773 | Antibodies Against the MUC1-C/EXTRACELLULAR Domain (MUC1-C/ECD) Formerly held In force · High confidence | In force | High confidence | |
| US 8,614,186 | Inhibition of Inflammation Using Antagonists of MUC1 Lapsed on the fee record Ended Dec 24, 2025 · High confidence | Lapsed on the fee record | Ended Dec 24, 2025 | High confidence |
| US 9,096,687 | Inhibition of Inflammation Using Antagonists of MUC1 Lapsed on the fee record Ended Aug 4, 2023 · High confidence | Lapsed on the fee record | Ended Aug 4, 2023 | High confidence |